Novartis Announces Failure of Ruxolitinib Trial in Severe ... | 合法藥品大搜索

Read More

Ruxolitinib 是一種具有選擇性的Janus 激酶(JAKs) JAK1 與JAK2 的抑制劑( 對JAK1 與JAK2 酵素的IC50值分別為3.3 nM 與2.8 nM)。這些激酶可媒介許多對造血作用 ... Read More

2019年2月14日 — 新藥介紹：Ruxolitinib. 骨髓纖維化是一種罕見的造血功能失調之疾病，學理上可分為原發性或次發性。原 ... Read More

Ruxolitinib is an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib ... Read More

2020年12月18日 — RUXCOVID (NCT04362137) is a Phase III, multicenter, randomized, double-blind study that evaluated the safety and efficacy of ruxolitinib plus ... Read More

由 C Harrison 著作 · 2012 · 被引用 49 次 — Ruxolitinib therapy produces remarkable effects on splenomegaly and systemic symptoms, control of leukocytosis and thrombocytosis in most patients, overall ... Read More

由 J Mascarenhas 著作 · 2012 · 被引用 151 次 — Initially called INCB18424, ruxolitinib (Jakafi; Incyte), a potent JAK1/2 inhibitor, was the first drug of this class to enter clinical trials, and it is ... Read More

2019年8月15日 — Ruxolitinib is in a class of medications called kinase inhibitors. It works to treat myelofibrosis and PV by blocking the signals that cause cancer ... Read More

Learn about Jakafi® (ruxolitinib) – Used to treat adults with polycythemia vera who have taken hydroxyurea and it did not work well enough or they could not ... Read More

由 S Ajayi 著作 · 2018 · 被引用 22 次 — Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2. Ruxolitinib has been approved ... Read More